Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 11/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | LATS1 | O95835 | 1/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19709294 | 1.00 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3HTR2C | |
| SCHEMBL21098421 | 1.00 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3HTR2C | |
| SCHEMBL19709299 | 0.84 | ADRB1 (0.60) | CHRNB2CHRNA4HTR2CHTR2BTGFBR1 | |
| SCHEMBL17884782 | 0.81 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3LATS1 | |
| SCHEMBL30609705 | 0.81 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3LATS1 | |
| SCHEMBL2005355 | 0.81 | ADRB1 (0.56) | HTR2CHTR2BADRB1 | |
| SCHEMBL30609634 | 0.80 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3HTR2C | |
| SCHEMBL30609715 | 0.80 | ADAMTS5 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3HTR2C | |
| SCHEMBL17884677 | 0.80 | ADAMTS5 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3HTR2C | |
| SCHEMBL17884838 | 0.80 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498715-B1 | ANTI-HCMV VIRUS COMPOUND | MEDSHINE DISCOVERY INC (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-10851112-B2 | Anti-HCMV virus compound | MEDSHINE DISCOVERY INC. (CN) | 2020-12-01 | — | — | US | disclosed |
| US-20190202838-A1 | ANTI-HCMV VIRUS COMPOUND | PHAENO THERAPEUTICS CO., LTD. (CN) | 2019-07-04 | — | — | US | disclosed |
| EP-3498715-A1 | ANTI-HCMV VIRUS COMPOUND | Medshine Discovery Inc. (CN) | 2019-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202838-A1 | ANTI-HCMV VIRUS COMPOUND | RPL35, RPL5, RPL17 | CHRNB2 4782/4885CHRNA4 4376/4885CHRNB4 4711/4885 |
| US-10851112-B2 | Anti-HCMV virus compound | RPL35, RPL5, RPL17 | CHRNB2 4782/4885CHRNA4 4376/4885CHRNB4 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.